Abstract

Long-term liver inflammation can lead to severe liver conditions, including cancer. The antlered form of Ganoderma lucidum (G. lucidum AF) and Taiwan red quinoa have been shown to contain potent ingredients, like ganoderic acid, Ganoderma polysaccharides, and rutin, known for their antioxidant, anti-inflammatory and hepatoprotective properties. This study aimed to harness the antioxidant, antiinflammatory, and hepatoprotective properties of the antlered form of G. lucidum AF and red quinoa, also known as red quinoa, to create a compound extract granulated powder (GQE). The extraction process was scaled up using a 300-L extractor, yielding a granulated powder containing ganoderic acid A, rutin and Ganoderma polysaccharide. Efficacy was assessed in a mouse model with carbon tetrachlorideinduced liver fibrosis. Results revealed reduced levels of liver function indicators (aspartate transaminase and alanine transaminase) in the GQE-administered group. GQE also mitigated liver cell damage and collagen buildup. Additionally, GQE significantly reduced the expression of tumor necrosis factor-α and interleukin-6, thereby alleviating liver inflammation. For liver fibrosis, GQE effectively decreased the expression of connective tissue growth factor, transforming growth factor β1, and α-smooth muscle actin, thereby inhibiting excessive extracellular matrix accumulation. Hence, the compound product of G. lucidum AF and red quinoa holds potential as a functional extraction powder to ameliorate liver fibrosis.

Keywords:Liver fibrosis; Antlered form of Ganoderma lucidum; Red quinoa; Extraction trial production; Extract granulated powder